Can transmissible strains of Pseudomonas aeruginosa be successfully eradicated?

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1483-1486

  Gilchrist, F J ^a   France, M ^a   Bright Thomas, R ^a   Doherty, C J ^c   Govan, J R ^c   Webb, A K ^a,b   Jones, A M ^a,b  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ERADICATION THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LETTER; LUNG FUNCTION; MALE; PNEUMOTHORAX; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82555195181     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00048611     Document Type: Letter

References (10)

1. Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358: 557-558. (Pubitemid 32772734)
2. Cheng K, Smyth RL, Govan JR, et al. Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639-642. (Pubitemid 26293808)
3. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002; 166: 983-987. (Pubitemid 35193230)
4. Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010; 304: 2145-2153.
5. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100. (Pubitemid 34809519)
6. Jones AM. Eradication therapy for early Pseudomonas aeruginosa infection in CF: many questions still unanswered. Eur Respir J 2005; 26: 373-375. (Pubitemid 41264195)
7. UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic Treatment for Cystic Fibrosis. 3rd Edn. Bromley, Cystic Fibrosis Trust, 2009.
8. Lee TWR, Brownlee KG, Denton M, et al. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional paediatric cystic fibrosis center. Pediatr Pulmonol 2004; 37: 104-110. (Pubitemid 38120979)
9. Jones AM, Dodd ME, Govan JRW, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med 2005; 171: 257-260.
10. Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother 2010; 65: 2373-2375.